International Experts Discuss OptiTROP-Lung06: ADC Plus Immunotherapy Challenges the First-Line Standard in PD-L1-Negative NSCLC

International Experts Discuss OptiTROP-Lung06: ADC Plus Immunotherapy Challenges the First-Line Standard in PD-L1-Negative NSCLC

The 2026 Congress of the European Society for Medical Oncology (ESMO) was held in Madrid, Spain, from October 23 to 27. At this premier global oncology event, the OptiTROP-Lung06 study, led by Professor Caicun Zhou of Shanghai East Hospital, presented its findings in a major oral presentation, with simultaneous publication in the New England Journal of Medicine (NEJM). This Phase III study provided the first head-to-head evidence that the TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) plus pembrolizumab was superior to the standard regimen of platinum-based doublet chemotherapy plus pembrolizumab as first-line treatment for patients with driver gene-negative, PD-L1-negative (expression <1%) nonsquamous non-small cell lung cancer (NSCLC).
ESMO Voices from China | Professor Shaodong Hong: TROP2 ADC Plus Immunotherapy in First-Line NSCLC — Encouraging Efficacy with BAT8008-Based Combination Therapy

ESMO Voices from China | Professor Shaodong Hong: TROP2 ADC Plus Immunotherapy in First-Line NSCLC — Encouraging Efficacy with BAT8008-Based Combination Therapy

For patients with advanced driver gene-negative non-small cell lung cancer (NSCLC), current first-line standard treatment primarily relies on immunotherapy alone or immunotherapy combined with chemotherapy. However, long-term patient outcomes still need to be further improved. Antibody-drug conjugates (ADCs) targeting trophoblast cell-surface antigen 2 (TROP2), through their dual mechanisms of cytotoxicity and immune activation, may enhance the effects of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade.
ESMO Insights from China | Professor Xiaohua Wu: Four Chinese-Originated Studies Reshape the Treatment Landscape in Gynecologic Oncology

ESMO Insights from China | Professor Xiaohua Wu: Four Chinese-Originated Studies Reshape the Treatment Landscape in Gynecologic Oncology

The 2026 Congress of the European Society for Medical Oncology (ESMO 2026) was held in Madrid, Spain, from October 23 to 27. At this year's congress, the team led by Professor Xiaohua Wu from Fudan University Shanghai Cancer Center presented four studies of innovative drugs developed in China, spanning three major gynecologic malignancies: cervical cancer, ovarian cancer, and endometrial cancer.
Expert Commentary by Professor Yilong Wu: The Evolution of Molecularly Driven Precision Stratification and Comprehensive Treatment Strategies in Lung Cancer

Expert Commentary by Professor Yilong Wu: The Evolution of Molecularly Driven Precision Stratification and Comprehensive Treatment Strategies in Lung Cancer

In driver gene-positive non-small cell lung cancer (NSCLC), mesenchymal-epithelial transition factor (MET) abnormalities represent an important bypass resistance mechanism in patients with epidermal growth factor receptor (EGFR) mutations. Primary MET overexpression is also often associated with poor efficacy of EGFR tyrosine kinase inhibitor (TKI) monotherapy. How to overcome resistance through precision treatment and achieve more refined patient stratification in the first-line setting remain pressing challenges for the global lung cancer community.
Fudan University Shanghai Cancer Center Leads Global Collaboration to Propose New International Staging Systems for Two Aggressive Thyroid Cancers

Fudan University Shanghai Cancer Center Leads Global Collaboration to Propose New International Staging Systems for Two Aggressive Thyroid Cancers

Although medullary thyroid carcinoma (MTC) and poorly differentiated thyroid carcinoma (PDTC) are relatively rare, they are more aggressive and associated with a higher risk of disease-related mortality. The TNM staging system of the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) serves as the global “common language” for cancer diagnosis, treatment, and research. Its primary role is to stratify patients by prognosis and provide a basis for postoperative surveillance, risk management, and stratification in clinical studies. However, the current eighth edition of the TNM system has notable limitations for both tumor types. In MTC, certain lymph node categories do not fully correspond to actual prognostic outcomes, potentially resulting in an excessive concentration of patients in advanced stages. PDTC, meanwhile, has long lacked an independent staging system and has had to rely on the framework for differentiated thyroid cancer, which does not adequately reflect its distinct biological behavior.
Global Health Dialogue | Academician Daming Fan: Sharing China’s Approach to Cancer Prevention and Control With the World

Global Health Dialogue | Academician Daming Fan: Sharing China’s Approach to Cancer Prevention and Control With the World

Recently, Academician Daming Fan, President of the Chinese Anti-Cancer Association (CACA), was invited to an exclusive interview with Princess Dina Mired of Jordan, former President of the Union for International Cancer Control (UICC). With a history spanning more than 90 years and members in over 170 countries, UICC is one of the world's most influential organizations in cancer control and prevention.